ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: FR-PO1122

University of California (UC) Kidney COVID-19 Study AKI Cohort

Session Information

  • COVID-19 - II
    November 03, 2023 | Location: Exhibit Hall, Pennsylvania Convention Center
    Abstract Time: 10:00 AM - 12:00 PM

Category: Coronavirus (COVID-19)

  • 000 Coronavirus (COVID-19)

Authors

  • Hamdan, Hiba, UC Davis Health, Sacramento, California, United States
  • Paciotti, Brian Michael, UC Davis Health, Sacramento, California, United States
  • Durbin-Johnson, Blythe, UC Davis Health, Sacramento, California, United States
  • Moreno-Ortiz, Juan Pablo, UC Davis Health, Sacramento, California, United States
  • Young, Brian Y., UC Davis Health, Sacramento, California, United States
  • Roshanravan, Baback, UC Davis Health, Sacramento, California, United States
Background

A wide range of rates of AKI associated with COVID-19 have been reported, often specific to select timeframes and associated SARS-CoV-2 variants of the pandemic. The aim of our study is to comprehensively describe the rates of AKI in people hospitalized with COVID-19 over the course of the first two years of the pandemic and identify risk factor for AKI in that population.

Methods

We conducted a retrospective cohort study of adults receiving care within the 5 major University of California (UC) Health Systems. The cohort included people who underwent PCR testing and were positive for SARS-CoV-2 between March 1, 2020, and December 31, 2021, and required hospitalization within 10 days of testing. The cohort was further restricted to those without ESKD, without documented pregnancy, and length of stay ≥1 day. To examine risk factors associated with AKI, we used a logistic model including age, gender, race, Area Deprivation Index (ADI), UC site of care, DM, HTN, heart failure, CKD, smoking status, BMI, use of NSAIDS at time of admission, use of ACEIs/ARBS at time of admission, ARDS, sepsis, mechanical ventilation, and month of COVID-19 diagnosis.

Results

The cohort included 5451 people with COVID-19. Patients had an average age of 59 years, 59% were male and 45% were Hispanic. From March 2020 to December 2021 the rates of AKI ranged from 20-38% and varied over the course of the pandemic (Figure 1). The factors associated with the highest odds (OR,95% CI) of AKI were: Black race (2.2,1.0-1.5), mechanical ventilation (5.1,4.2-6.2), sepsis (2.9,2.4-3.6), HTN (1.7,1.4-2.1) and CKD (1.5,1.1-2.0).

Conclusion

In a large cohort of people hospitalized with COVID-19, in one of the largest healthcare systems in California, AKI rates generally exceeded 25%. Black race, HTN, CKD, and in hospital sepsis and mechanical ventilation were associated with higher odds of AKI.

Funding

  • Other NIH Support